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Systemic lupus erythematosus (SLE) is the prototype autoimmune disease where genes regulated by type I
interferon (IFN) are over-expressed and contribute to the disease pathogenesis. Because signal transducer
and activator of transcription 4 (STAT4) plays a key role in the type I IFN receptor signaling, we performed
a candidate gene study of a comprehensive set of single nucleotide polymorphism (SNPs) in STAT4 in
Swedish patients with SLE. We found that 10 out of 53 analyzed SNPs in STAT4 were associated with SLE,
with the strongest signal of association (P 5 7.1 3 10
28) for two perfectly linked SNPs rs10181656 and
rs7582694. The risk alleles of these 10 SNPs form a common risk haplotype for SLE (P 5 1.7 3 10
25).
According to conditional logistic regression analysis the SNP rs10181656 or rs7582694 accounts for all
of the observed association signal. By quantitative analysis of the allelic expression of STAT4 we found
t h a tt h er i s ka l l e l eo fSTAT4 was over-expressed in primary human cells of mesenchymal origin, but not
in B-cells, and that the risk allele of STAT4 was over-expressed (P 5 8.4 3 10
25) in cells carrying the risk
haplotype for SLE compared with cells with a non-risk haplotype. The risk allele of the SNP rs7582694
in STAT4 correlated to production of anti-dsDNA (double-stranded DNA) antibodies and displayed a multi-
plicatively increased, 1.82-fold risk of SLE with two independent risk alleles of the IRF5 (interferon regulatory
factor 5) gene.
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Systemic lupus erythematosus (SLE, OMIM # 15200) is an
autoimmune disease characterized by production of antinuclear
autoantibodies, immune complex formation and inﬂammation
in multiple organs. Patients with SLE have raised serum levels
of IFN(interferon)-a, which correlates to both disease activity
and severity (1), and with an increased expression level of
type I IFN-regulated genes peripheral blood cells (an IFN
signature) (2–4). The reason for this IFN signature may be
an ongoing production of type I IFN, which is caused by
RNA- or DNA-containing immune complexes that trigger
plasmacytoid dendritic cells (DCs) to synthesize type I IFNs
via the Toll-like receptor (TLR) 7 or TLR9 (5). Because the
type I IFNs cause activation and maturation of DC, stimulation
of Th1 and Tc cells as well as enhanced immunoglobulin
production by B-cells, this mechanism of a continuous acti-
vation of the type I IFN system could be directly involved in
the etiopathogenesis of SLE (5,6).
We have previously observed that the interferon regulatory
factor 5 (IRF5) and tyrosine kinase 2 (TYK2) genes, which are
involved in both the production and the effects of the type I
IFNs are associated with susceptibility to develop SLE (7).
Theseobservationshavebeenreplicated inmultiplesubsequent
studies (8,9). The transcription factor IRF5 regulates the
expression of type I IFN genes, while the Janus kinase TYK2
bindstothetypeIIFNreceptor(IFNAR)andisrequiredforsig-
nalingthroughthisreceptor.Inaddition,IRF5isinvolvedincell
adhesion, apoptosis, cell cycle regulation and early immune
activation(10),whileTYK2interactswiththecellularreceptors
of IL(interleukin)-6, IL-10 and IL-12/23 cytokine families, in
addition to IFNAR (11). Thus, both IRF5 and TYK2 have
diverse functions in the immune system that can affect several
pathways in autoimmune reactions.
In order to identify other molecules within the type I IFN
system with a possible association with SLE, we studied the
signal transducer and activator of transcription 4 (STAT4)
transcription factor, which plays a key role in the IFNAR sig-
naling by being activated and translocated to the nucleus after
IFNAR ligation (12). In addition, STAT4 transmits signals
from the receptors of IL-12 and IL-23, and can therefore
contribute to autoimmune responses by affecting the functions
of several innate and adaptive immune cells (13). By analyz-
ing 53 single nucleotide polymorphisms (SNPs) in STAT4
for their association with SLE in Swedish patients and
Control individuals we identiﬁed a common risk haplotype
type for SLE formed by 10 SNPs in introns of STAT4.D u r i n g
the course of our study, an association of the SNP rs7574865
in STAT4, which tags this risk haplotype was found to be associ-
ated with SLE in three North American SLE-cohorts of Euro-
pean ancestry (14). Furthermore, two recently published
genome-wide association studies of SLE conﬁrmed this associ-
ation (15,16). In our study we show that the risk haplotype
identiﬁed in STAT4 is over-expressed in primary human
cells of mesenchymal origin, but not in transformed B-cells,
and that the risk haplotype of STAT4 is over-expressed in
mesenchymal cells (osteoblasts) carrying the risk haplotype,
compared with cells with the non-risks haplotype. We also
show that the risk allele of STAT4 correlates with increased
frequency of immunological manifestations in the SLE
patients, including production of anti-dsDNA (double-
stranded DNA) autoantibodies. Because IRF5 mediates type
I IFN production and STAT4 affects the response to type I
IFN, we also determined the joint effects of the risk alleles
of STAT4 and two recently identiﬁed independent risk alleles
of IRF5 with strong effects on SLE (17). This analysis
revealed a strong multiplicatively increased risk for SLE by
these three polymorphisms located in STAT4 and IRF5,
which are two of the most strongly associated SLE-genes
and belong to the same cell signaling pathway.
RESULTS
Identiﬁcation of risk alleles and one major risk
haplotype of STAT4 in SLE
The STAT4 gene located on chromosome 2q32.3 consists of
24 exons spanning a 120 kb region (Fig. 1).We genotyped
53 SNPs, distributed across STAT4, in DNA samples from
485 Swedish patients with SLE and 563 Control individuals
and observed 10 SNPs that yielded uncorrected P-values
,0.001, with P-values for the association signals calculated
by Fischer’s exact test ranging from 4.5   10
24 to 7.1   10
28
(Fig. 1, Supplementary Material, Table S2). The strongest
signal of association [odds ratio (OR) ¼ 1.71 with 95% conﬁ-
dence interval (CI) 1.40–2.08] was observed for two SNPs
located in intron 3 of STAT4, namely the SNPs rs10181656
and rs7582694, which are in perfect linkage disequilibrium
(LD) (r
2 ¼ 1) with each other in our genotype data. The 10
SNPs that display association signals with SLE are located
in introns 3–24 of STAT4, and are all correlated with the
most strongly associated SNPs rs10181656 and rs7582694
(r
2 . 0.41) (Fig. 1 and Supplementary Material, Table S3).
We constructed haplotypes using the genotype data from these
10 SNPs and tested the association of the formed haplotypes
with SLE (Table 1). This analysis deﬁnes a major
risk haplotype for SLE that occurs with a frequency of 0.24 in
the SLE-patients, compared with 0.17 in the Controls and is
strongly associated with SLE [unadjusted P-value ¼ 1.7  
10
25 and OR 1.59 (95% CI 1.28–1.98)]. By conditional logistic
regression analysis we found that the SNPs rs7582694 (or
rs10181656) that displayed the strongest signals of association
with SLE accounts for the association signals observed from
all other SNPs in STAT4 (Table 2). According to the haplotype
mapping (HapMap) phase II data there are ﬁve additional
SNPs in STAT4 that are in strong LD (r
2 . 0.9) with the
SNPs rs10181656 and rs7582694. These are: rs11889341 (r
2 ¼
1.0), rs7574865 (r
2 ¼ 1.0), rs7568275 (r
2 ¼ 1.0), rs8179673
(r
2 ¼ 0.95), rs10174238 (r
2 ¼ 0.90). One of them, rs7574865,
was recently shown to be associated with SLE with high signiﬁ-
cance (P ¼ 1.87   10
29,O R¼ 1.55) in SLE patients from the
US with European ancestry (14), and two consequent genome-
wide association studies conﬁrm this ﬁnding (15,16).
Allelic and total expression levels of STAT4
Because there are no known common coding SNPs in STAT4
that are in LD with the SLE-associated STAT4 SNPs, we
investigated if a possible functional role for these intronic
SNPs that accounted for the association signal with SLE
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two well-characterized isoforms, STAT4 a and b, which could
be relevant for SLE, because they have been shown to have
distinct functions in mediating the response to IL-12 in
Th1-cells from mice (18). In the STAT4b isoform, expression
of an additional exon introduces a stop codon in the STAT4
mRNA, which results in a truncated protein lacking a putative
transcriptional activation domain in its C-terminus. We tested
whether the disease-associated STAT4 SNPs would alter
expression of the alternatively spliced STAT4b isoform by uti-
lizing expression data from Affymetrix Exon 1.0 arrays in two
population-based panels of cells of both lymphoid (lympho-
blast) and mesenchymal (osteoblast) origin (19). We did not
ﬁnd evidence for association with the expression level of the
STAT4b isoform for any of the SLE-associated SNPs (data
not shown).
Next we determined the allelic expression levels of STAT4
(20) in pooled primary human osteoblast and pooled human
lymphoblast cell lines. The SNP rs8179673, which is in
almost perfect pair-wise LD (r
2 ¼ 0.95) with our two strongest
SLE-associated SNPs rs7582694 and rs10181656 was used as
indicator of allelic imbalance in pre-mRNA extracted from the
cells. This analysis showed that the SLE-risk allele of the SNP
rs8179673 was signiﬁcantly over-expressed in the pooled
osteoblasts (P ¼ 0.038), but not in the lymphoblasts (Fig. 2A
and B). Consequently, we determined the allelic expression
levels of the SLE-risk haplotype of STAT4 in 10 informative
individual osteoblasts for which the SLE-risk haplotype
could be unequivocally assigned and which were heterozygous
for at least two of the SNPs rs1517352, rs3821236 and
rs7574865 used as indicators of allelic imbalance. The SNP
rs1517352 and rs3821236 were genotyped in our SLE
samples (Table 2, Supplementary Material, Table S3), and
the SNP rs7574865 is in perfect LD (r
2 ¼ 1.0) with our two
strongest SLE-associated SNPs. We observed signiﬁcant over-
expression of the SLE-risk haplotype in each of the osteoblasts
carrying the SLE-risk haplotype, compared with its expression
in osteoblasts with a non-risk haplotype (P ¼ 8.4   10
25)
(Fig. 2C). We also determined the total expression level of
STAT4 in 40 individual osteoblasts with known STAT4 haplo-
type status using data from Illumina Human Ref-8 Bead
Arrays and found that STAT4 mRNA was over-expressed in
osteoblasts carrying the risk haplotype for SLE (P ¼ 0.0085)
compared with osteoblasts with non-risk haplotypes (Fig. 2D).
Correlation between risk allele of STAT4 and disease
phenotype
Information concerning disease manifestations and genotype
data for the STAT4 SNP rs7582694 were available for 475
SLE patients included in the association analysis described
earlier, and from an additional cohort of 220 Swedish SLE
patients. We correlated the presence of at least one risk
allele with age at diagnosis of SLE, individual American
College of Rheumatology (ACR) criteria, total number of
ACR criteria and the presence of antibodies against dsDNA.
We found that patients with at least one risk allele of STAT4
Figure 1. Schematic view of the genetic variation of STAT4. The positions of the exons are marked with vertical lines and the translation start site is indicated by
an arrow. The negative log10 of the P-value for the association of each SNP with SLE determined by Fisher’s exact test is shown by a dot in the diagram. The
pair-wise LD r
2-values between the SNPs in STAT4 according to the combined data from the Swedish SLE patients and Controls are shown in the lower part of
the ﬁgure. The exact LD values (D’ and r
2) are provided in Supplementary Material, Table S3.
Table 1. Haplotype analysis of 10 SNPs in STAT4 associated with SLE
Haplotypes
a Haplotype
frequencies
b
P-values
c OR (95% CI)
d
Cases Controls
H1 GGCCGCTCGC 0.50 0.59 5.8E205 0.70 (0.59–0.84)
H2 AATAATCGCG 0.24 0.17 1.7E205 1.59 (1.28–1.98)
H3 GGTAACCCGC 0.06 0.07 0.59 0.91 (0.64–1.29)
H4 GGCAACCCGG 0.04 0.06 0.028 0.62 (0.40–0.95)
H5 GGCAACCGCG 0.05 0.04 0.058 1.51 (0.98–2.31)
H6 GGCCGCCCGG 0.02 0.02 0.90 1.04 (0.55–1.95)
H7 GGTAACCGCG 0.02 0.01 0.29 1.44 (0.73–2.85)
aThe 10 SNPs included in the analysis are in order from left to right:
rs3024886, rs3821236, rs3024877, rs1517352, rs13017460, rs10168266,
rs16833249, rs10181656, rs7582694 and rs16833260.
bHaplotype frequencies estimated using Haploview v. 4.0.
cUnadjusted P-values by x
2 test using Haploview v 4.0.
dOdds ratio (OR) and 95% conﬁdence interval (CI) calculated using the
formula (a   d)/(b   c) where a and b are the haplotype counts in Cases and c
and d are the haplotype counts in Controls.
2870 Human Molecular Genetics, 2008, Vol. 17, No. 18had a higher frequency of immunological disorder (unadjusted
P-value ¼ 1.6   10
25) and presence of antibodies against
dsDNA (unadjusted P-value ¼ 5.3   10
27) than patients
with no risk alleles (Table 3).
Additive effects of the risk alleles of STAT4 and IRF5
in SLE
We have recently analyzed a comprehensive set of polymorph-
isms in IRF5 located on chromosome 7q32 for their associ-
ation with SLE in the same SLE patients and Controls that
were here analyzed for SNPs in STAT4 (17). We demonstrated
that two independently associated polymorphisms in IRF5
account for the association signals with SLE, namely a pre-
viously unknown 5 bp (CGGGG) indel (insertion–deletion)
in the promoter region of IRF5 (OR ¼ 1.69, 95% CI 1.42–
2.02) and the SNP rs10488631 or one of multiple perfectly
correlated SNPs located 30 of IRF5 (OR ¼ 2.07, 95% CI
1.63–2.62). In the present study we investigated the joint
effect on SLE of the risk allele of the SNP rs7582694 in
STAT4 and the two polymorphisms in IRF5. Figure 3A
shows the distribution of risk alleles for SLE in STAT4 and
IRF5 in patients and Controls. The overall signiﬁcance for the
difference in risk allele counts between patients and Controls
Table 2. Conditional logistic regression analysis of SNPs in the STAT4 gene in
SLE
SNP ID Unadjusted P-values
Single marker
a
Conditional
b
on rs7582694
rs3024908 0.16 0.22
rs3024904 0.17 0.24
rs3024936 0.81 0.91
rs3024935 0.83 0.92
rs3024896 0.04 0.94
rs925847 0.53 0.23
rs3024886 3.0E205 0.83
rs3821236 4.8E205 0.93
rs3024877 5.9E205 0.46
rs12999858 0.76 0.51
rs1400654 0.04 0.14
rs3771327 0.02 0.09
rs3024866 1.7E203 0.65
rs3024851 0.03 0.12
rs932169 0.53 0.77
rs1517352 4.4E204 0.63
rs13017460 5.1E204 0.68
rs13389408 0.04 0.44
rs1400656 0.04 0.15
rs10168266 5.1E205 0.80
rs7594501 0.04 0.21
rs2459611 0.81 0.58
rs7601754 0.11 0.79
rs3024921 0.69 0.72
rs16833249 2.8E204 0.80
rs12998748 0.48 0.76
rs6434435 0.85 0.26
rs10181656 8.8E208 NA
rs7582694 8.8E208 NA
rs16833260 3.5E205 0.55
rs6752770 0.05 0.56
rs7599504 0.27 0.60
rs4853543 0.61 0.37
rs4073699 0.44 0.46
rs17769077 0.85 0.92
rs4341967 0.73 0.28
rs10931483 0.70 0.29
rs4583497 0.58 0.38
rs4555370 0.69 0.32
rs10804037 0.69 0.31
rs17769459 0.65 0.91
rs6712821 0.63 0.36
rs1551443 0.62 0.37
rs7566274 0.61 0.39
rs2356350 0.98 0.23
rs10189819 0.57 0.62
rs7596818 0.44 0.81
rs11685878 0.58 0.99
rs4853546 0.43 0.79
rs1031509 0.75 0.93
rs10497711 0.74 0.73
rs7572482 0.78 0.77
rs897200 0.93 0.95
aUnadjusted P-value for the association with SLE based on additive
logistic regression.
bP-valuefor theassociation usingadditivelogisticregressionconditionalonthe
indicated marker. NA indicates that the marker cannot be distinguished from
the conditional model.
Figure 2. Expression analysis of STAT4. Allelic expression analysis of STAT4
in (A) pooled primary human osteoblasts (n ¼ 55) derived from unrelated
Swedish individuals and (B) pooled human lymphoblastoid cell lines (n ¼
55) derived from unrelated individuals of European descent (the HapMap
CEU individuals). The mean values of ratios (with SD in error bars)
between the alleles (C/T) of the indicator SNP rs 8179673 in triplicate RNA
samples compared with normalized heterozygote ratios in triplicate DNA
samples from the corresponding cells are shown. (C) Allelic expression analy-
sis of the SLE-risk haplotype of STAT4 in informative individual primary
osteoblasts (n ¼ 10) for which the STAT4 SLE-risk haplotype status is
known and that are heterozygous for at least two of the indicator SNPs
rs1517352 (A/C), rs 3821236 (A/G) and rs7574865 (G/T). The normalized
mean (with SD in error bar) allelic expression levels of the SLE-risk haplotype
of STAT4 in each cell sample are shown for osteoblasts with the SLE-risk and
non-risk haplotype, respectively. (D) Total expression analysis of individual
primary osteoblasts with known STAT4 haplotype status using Illumina
Human Ref-8 Bead Arrays. Mean normalized total expression levels (log2
value on y-axis and SD of the mean in error bars) for homozygous (þ/þ,
n ¼ 1) and heterozygous (þ/2, n ¼ 16) carriers of the SLE-risk haplotype of
STAT4 (total n ¼ 17) and non-carriers (2/2) of the risk haplotype (n ¼ 23)
are shown.
Human Molecular Genetics, 2008, Vol. 17, No. 18 2871in all groups is high, with a one-sided P-value of 1.7   10
216,
using an additive logistic regression model. No evidence for
dominance or interactions was observed between the three risk
alleles using multiple logistic regression analysis. Figure 3B
shows the OR for SLE in the group of patients with two or
more risk alleles, using the individuals with zero or one risk
allele as reference. As can be seen, the risk of SLE increases
as a function of the number of risk alleles in a multiplicative
manner with a 1.82-fold increase in OR for each additional
risk allele. The OR for SLE is 2.08 (CI 1.53–2.83) for carriers
of two risk alleles and 13.0 (3.78–44.3) for carriers of ﬁve or six
risk alleles when compared with those with zero or one risk
allele. No convincing correlation was found when the risk
alleles in STAT4 and IRF5 were combined and correlated to
disease phenotype in the patients with SLE (data not shown).
DISCUSSION
In the present investigation we analyzed a panel of SNPs that
capture the majority of the common variation of STAT4 for
their association with SLE, and identiﬁed 10 SNPs with
strong association signals. This result conﬁrms a role of
STAT4 in SLE and corroborates previously reported obser-
vations of an association between individual SNPs in STAT4
and risk to develop SLE (14–16). In our study the risk
alleles of two highly correlated SNPs account for all associ-
ation signals observed and deﬁne a single common risk haplo-
type with a strong association with SLE. However, we cannot
exclude rare SNP alleles or other types of polymorphisms than
SNPs as risk alleles for SLE. Identiﬁcation of possible
additional risk alleles must await complete re-sequencing of
STAT4 in SLE patients and Controls.
When investigating the consequences of the risk allele on
the expression of STAT4, we observed an increased expression
of the risk allele of STAT4 in primary cells of mesenchymal
origin (human osteoblasts), but not in transformed B-cells,
which provides a functional hypothesis of the disease associ-
ation in SLE. We recently demonstrated in comparative tran-
scriptome analysis that human osteoblasts are closely related
to human ﬁbroblasts and chondrocytes (21). Interestingly
STAT4 was one of the most signiﬁcantly over-expressed
genes in the osteoblasts as compared with the two other
Table 3. Correlation between the STAT4-risk allele of the SNP rs7582694 and
disease phenotype
Clinical criterion Frequency
for all
patients
(n ¼ 695)
Frequency for patients with P-value
a
0 risk allele
(n ¼ 300)
1 or 2 risk
alleles
(n ¼ 395)
Malar rash
(ACR1)
b
0.59 0.60 0.59 0.70
Discoid rash
(ACR2)
0.25 0.28 0.24 0.19
Photosensitivity
(ACR3)
0.69 0.71 0.67 0.36
Oronasal ulcers
(ACR4)
0.25 0.23 0.25 0.59
Arthritis
(ACR5)
0.77 0.79 0.76 0.32
Serositis
(ACR6)
0.45 0.42 0.47 0.17
Nephritis
(ACR7)
0.32 0.27 0.35 0.040
CNS
(ACR8)
0.12 0.13 0.11 0.72
Hematological
(ACR9)
0.60 0.56 0.63 0.073
Immunological
(ACR10)
c
0.66 0.57 0.73 1.6   10
25
ANA
(ACR11)
0.98 0.98 0.98 0.79
Anti-dsDNA Ab
ever
c
0.54 0.43 0.62 5.3   10
27
Number of ACR
criteria
d
5.6+1.4 5.5+1.3 5.8+1.4 0.022
Age at diagnosis
d 35.5+14.9 36.7+15.4 34.5+14.5 0.11
aFrequency of patients with 0 risk alleles compared with patients with 1 or
2 risk alleles fulﬁlling each clinical criterion, unadjusted P-value
calculated by Fisher’s exact test.
bAmerican College of Rheumatology (ACR) classiﬁcation criteria (39).
cAntibodies to double-stranded DNA (dsDNA) is part of the immunological
criterion.
dMean value with 1 SD.
eUnadjusted P-value calculated with the Mann–Whitney U test.
Figure 3. Joint effects of risk alleles of STAT4 and IRF5.( A) Distribution of
the number of patients and Controls according to number of risk alleles of
SLE. The risk alleles are the C-allele of the SNP rs7582694 in STAT4 and
the longer allele (4  CGGGG) of the 5 bp indel polymorphisms and the
C-allele of the SNP rs10488631 in IRF5. The black bars indicate patients
and the light gray bars indicate Controls. The P-values are for the difference
in allele counts between patients and Controls in the groups with two or more
risk alleles, as compared with the groups with zero or one risk allele.
(B) Linear regression analysis showing a multiplicative effect of the risk
alleles of the SNP rs7582694 in STAT4 and of the longer allele of the 5 bp
indel polymorphisms and the C-allele of the SNP rs10488631 in IRF5 on
SLE. The OR with 95% CI are shown as a function of number of risk
alleles of SLE. The slope of the line corresponds to a 1.82-fold increase in
OR for each additional risk allele.
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that are associated with SLE are located in introns and could
regulate the expression level or splicing of STAT4. Indeed,
we show evidence supporting the former alternative, because
the common risk haplotype alters expression of STAT4 only
in one of the cell types analyzed. Thus, our results indicate
the potential presence of a tissue-speciﬁc intragenic enhancer,
the function of which could be perturbed by common variants
within the SLE-risk haplotype. Obviously, different gene var-
iants may have different effects on the expression of STAT4
between cell types, which could at least partially explain the
diverse effects by STAT4 in many different cells of the
immune system (13).
In our study we also observed a correlation between the risk
allele of STAT4 and a higher frequency of antibodies against
dsDNA among patients with the risk allele, which suggests
that polymorphisms in STAT4 contribute to the underlying
autoimmune process in SLE. This effect could be due to the
many different effects of STAT4 in the immune system.
Besides its role in type I IFN signaling, STAT4 also transmits
signals from, e.g. IL-12 and IL-23, and is thus responsible for
the IL-12-dependent activation of natural killer (NK) cells and
production of IFN-g, as well as for polarization of naı ¨ve
CD4þ T-cells to IFN-g producing Th1 effector cells (11).
Recent studies also indicate that STAT4 regulates the
IL-23-dependent expansion of TH17 cells, which are key
actors in the proinﬂammatory immune response (22). As DC
maturate functionally, they express more STAT4, which is
required for efﬁcient presentation of antigen (23). Activation
of STAT4 is also responsible for the IL-12-induced production
of IL-10 in murine NK cells (24) and Th1 cells (25). In the
presence of type I IFN, IL-10 becomes mainly proinﬂamma-
tory instead of anti-inﬂammatory (26). Thus, STAT4 has
pleiotropic and mostly stimulatory effects in the immune
system, and has been described as a critical regulator of
inﬂammation in vivo, including the development of auto-
immune diseases (13). A risk haplotype for SLE, which is
associated with increased expression of STAT4, as suggested
by our data from osteoblasts, is therefore of great interest.
The complex role of STAT4 in vivo is illustrated by the obser-
vation that STAT4-deﬁcient lupus mice have aggravated
nephritis and increased mortality, despite the fact that they
have decreased autoantibody levels and complement depo-
sitions in the kidneys (27).
We have argued for a pivotal role of the type I IFN system in
autoimmune diseases, including SLE (5). It has been proposed
that type I IFNs stimulate an early autoimmune response, but
mayalsolaterinhibitanongoingautoimmuneresponse(28).Poss-
ible inhibition of the autoimmune response by type I IFNs could
occur via increased concentration and activation of STAT1
mediated by the type I IFNs, which would decrease the function
of STAT4, at least in part due to competition between STAT1
and STAT4 for binding to the IFNAR (29,30). Therefore, it is
possible that altered regulation of the expression of STAT in
SLE may allow continued type I IFN stimulation of the STAT4-
dependent autoimmune response.
Several transcription factors have been found to interact with
the promoter of the STAT4 gene, increasing its expression,
including AP-1 and the NF-kB (31). At least in DC, the proin-
ﬂammatory cytokines TNF-a and IL-1 are potent stimulators
of STAT4 expression via activation of NF-kB (31). Interest-
ingly, IRF5 is major mediator of TLR-triggered expression
of other proinﬂammatory cytokines than type I IFN, such as
TNF-a (32), and in this way IRF5 could promote expression
of the STAT4 gene. Thus STAT4 and IRF5, which both
contain polymorphisms that confer increased risk for SLE, are
also functionally linked.
When we determined the joint effect of the risk alleles of
STAT4 and two recently identiﬁed independent risk alleles in
IRF5, we observed a multiplicative increase in OR by a
factor of 1.82 for each additional risk allele and a considerably
increased risk of SLE (OR ¼ 5.83) for those 18% of the SLE
patients who carried four or more risk alleles. The importance
of this ﬁnding is accentuated by the results of one of the
recently published genome-wide SNP association studies,
which deﬁnes STAT4 and IRF5, along with HLA-DQA1 as
the loci that display the strongest association with SLE
among all human genes (16). These observations, as well
as the ﬁndings that polymorphisms in the STAT4 are also
associated with rheumatoid arthritis (RA) (14,33), and that
polymorphisms in IRF5 are associated with RA (34), inﬂam-
matory bowel diseases (IBD) (35) and multiple sclerosis
(MS) (36), suggest that STAT4 and IRF5 can contribute to a
general loss of tolerance, whereas other genes might contrib-
ute to the disease-speciﬁc phenotypes. In this respect IRF5
may be unique because the CGGGG indel polymorphisms in
IRF5 is associated with SLE (17), IBDs (35) and MS (36),
and thus seems to promote the autoimmune process. In con-
trast, the SNP rs10488631 and several proxies of this SNP
downstream of IRF5 are associated only with SLE and thus,
appear to promote the disease-speciﬁc phenotype.
Our study demonstrates a strongly increased risk of SLE in
individuals carrying multiple risk alleles of two genes from the
type I IFN signaling pathway. When more susceptibility genes
of SLE, or even a complete set of susceptibility genes have
been identiﬁed, a signature of multiple risk alleles could be
used to improve disease prediction (37). The observed connec-
tion between the risk allele of STAT4 and production of SLE-
speciﬁc autoantibody also indicates that a genetic signature of
risk alleles could be used in the future for improved classiﬁ-
cation of patients with SLE compared with the current ACR
criteria. Combined genotype data from genes in the same or
related molecular pathways may also be helpful when studying
interactions between genes and the environment, for instance
the susceptibility to disease ﬂare during viral infections that
is apparent in a subset of SLE patients (38).
MATERIALS AND METHODS
Patients and Controls
Our study included 485 Swedish SLE patients fulﬁlling at least
four of the classiﬁcation criteria for SLE as deﬁned by the ACR
(39) and 563 matched healthy Control individuals from
the same geographic areas as the patients. The patients were
from the rheumatology clinics at the Lund (n ¼ 144), Uppsala
(n ¼ 136) and Karolinska (Solna) (n ¼ 205) University Hos-
pitals. The SLE patients had a mean age at disease diagnosis of
33.8+14.2 years (range 9–75). Disease manifestations were
scored in accordance with the ACR criteria (39) and the mean
Human Molecular Genetics, 2008, Vol. 17, No. 18 2873numberofcriteriafulﬁlledwas5.7+1.4(range4–10)outofthe
11ACRcriteria.TheControl samplesfromLund(n ¼ 195)con-
sisted of healthy blood donors from the same region as the
patients. The Control samples from Uppsala (n ¼ 155) were
from healthy blood donors that were matched with the patients
forage,sexandregionofliving.TheControlsamplesfromStock-
holm (n ¼ 213) were population-based Control individuals
matched for age and sex with the patients. DNA was extracted
from blood samples of the patients and Controls using standard
procedures.ForcorrelationofSTAT4genotypewithdiseasephe-
notypewealsoincluded220SLEpatientsfromtherheumatology
clinic of Umea ˚ Univeristy Hospital. These patients had a mean
age of diagnosis of 39.1+15.7 years and a mean number of ful-
ﬁlled ACR criteria of 5.4+1.4. For studying the expression of
the STAT4 gene we used Epstein-Barr virus (EBV)-transformed
human B-cells (lymphoblastoid cells) from the Human Hap
Map Caucasian panel, which is derived from individuals of
northern European descent (40) and human primary cells of
mesenchymal origin (osteoblasts) derived from unrelated
Swedish donors undergoing elective hip replacement surgery
at Uppsala University Hospital. The human osteoblasts were
cultured as described earlier (41). The study was approved by
the regional ethical boards and all study subjects gave their
informed consent to participate.
Genotyping
Forgenotypingweselected64SNPsfromtheSTAT4gene,from
2 kb upstream of the ﬁrst exon to 2 kb downstream of the last
exon, thus including all exons and introns (Supplementary
Material, Table S1). The goal of the SNP selection was to
cover the STAT4 gene region with approximately one SNP
per 2 kb. The selection was guided by the Illumina Golden
Gate Assay design scores and by the HapMap phase II data
(20 January 2006 release, NCBI assembly B35, dbSNP b125).
AnIlluminascoreof0.6wasusedasthelowerlimitforinclusion
in the panel. Tag-SNP information was obtained from the
HapMap website, and for each group of SNPs in high LD
(r
2 . 0.95, minor allele frequency .0.05) at least one SNP
was selected. The selected panel of 64 SNPs was genotyped in
DNAsamplesfromtheSwedishpatientswithSLEandControls
from Lund, Uppsala and Stockholm using the Golden Gate
Assay (Illumina Inc., San Diego, CA, USA). Of the 64 SNPs
genotyped, seven were non-polymorphic, two failed due to
poor genotype clustering and the genotypes of two SNPs
deviated form Hardy–Weinberg equilibrium in the Controls
(P , 0.01). These SNPs were excluded from further analysis.
For the 53 SNPs that fulﬁlled the quality control criteria, the
sample success rate was 96.7% and the average genotype call
rate in these samples was 99.7%. Four parent–offspring trios
were included in the genotyping for inheritance check, and no
Mendelian inheritance errors were observed. Thirty-two
samples were genotyped in duplicates with the Golden Gate
Assay with 100% consistency between genotype calls. The 53
successfullygenotypedSNPscapture91%oftheHapMapSNPs
(MAF . 0.05) with r
2 . 0.8. The IRF5 SNP rs10488631 was
genotyped by the Illumina Golden Gate Assay and the 5 bp
(CGGGG) indel polymorphism of IRF5 was genotyped by
polymerase chain reaction (PCR) ampliﬁcation followed by
size separation by electrophoresis using 4% agarose gels, or
using an ABI 3770 capillary sequencer (Applied Biosystems,
Foster City, CA, USA) as previously described (17). The SNP
rs7582694 in STAT4 was genotyped in the SLE patients from
Umea ˚ using the SNPstream system (Beckman-Coulter Inc.,
Fullerton, CA, USA). The genotyping success rate was 90.6%
and the reproducibility of genotyping was 100% according to
6% duplicated genotyping assays.
Expression analysis of STAT4
The STAT4b isoform-speciﬁc expression was determined
with Affymetrix Exon 1.0 arrays (Affymetrix, Santa Clara,
CA, USA) using isoform-speciﬁc probe sets 2592363 at
chr2:191604056–191604086 and 2592364 chr2:191604199–
191604358 according to the procedures recommended by
Affymetrix. The complete data set for the EBV-transformed
human B-cells (n ¼ 57) has been described previously (19),
and the complete data set for the human primary osteoblasts
(n ¼ 58) generated by the same procedures will be published
separately. Allelic expression levels of STAT4 were assessed
in pooled lymphoblasts (n ¼ 55) and osteoblasts (n ¼ 55). The
allele ratios were determined by quantitative sequencing of
RT(reverse transcriptase)–PCR products from pre-mRNA and
PCR product from genomic DNA in the pooled samples (42).
Allelic expression ratios in the RNA samples were calculated
using normalized heterozygote ratios from genomic DNA
from the same cells as reference (42). The SNP rs8179673
was used as indicator of allelic imbalance in the expression of
STAT4 in the pooled samples. The sensitivity of pooled RNA
analysis in the EBV-transformed human B-cells was assessed
using known loci (n ¼ 13) with allelic differences in expression
in individual cell lines from previous studies by us (20) and
others (43,44). Of these 13 loci, 12 (92%) showed statistically
signiﬁcant over-expression of the expected allele in the pooled
analysis (D.J. Verlaan, E. Grundberg, B. Ge, R. Hoberman,
K. Lam, V. Koka, J. Dias, S. Gurd, N. Martin, O ¨. Ljunggren,
O. Nilsson, A. Kindmark, H. Brandstro ¨m, E. Harmsen and
T. Pastinen, manuscript in preparation). The individual osteo-
blasts have been genotyped for about half a million SNPs
using Illumina 550K SNP Bead Arrays (Illumina Inc.). This
data was used for assigning STAT4 haplotypes to the individual
osteoblasts using an algorithm in Phase 2.1 as described
previously (45). Osteoblasts (n ¼ 10) for which the haplotype
could be accurately assigned using this method, and which
were heterozygous for at least two out of the three SNPs
rs1517352, rs3821236 and rs7574865 used as indicators of the
SLE-risk haplotype, were included in the allelic expression
analysis of STAT4 (42). The mean values of triplicate measure-
ment of the allelic expression levels determined using two or
three heterozygous SNPs were used. The total expression
level of STAT4 was determined in osteoblasts with known
STAT4 haplotype (N ¼ 40) in two biological replicates with
Human Ref-8 Bead Arrays from Illumina Inc. using the probe
ILMN_8937. A variance-stabilizing transformation, which
takes advantage of a large number of technical replicates avail-
able from the Illumina BeadArrays was coupled with a robust
spline normalization to obtain normalized mean expression
values (46).
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Fisher’s exact test was used to test for Hardy–Weinberg equili-
briumintheControlsamplesandforcomparingtheallelecounts
in the Cases and Controls. Association tests, calculation of OR
and conditional logistic regression analysis were performed
using the software PLINK. LD was calculated using Haploview
v 4.0. The expression level of the STAT4b isoform was
correlated with the genotypes of the SLE-associated SNPs in
STAT4 using a linear regression model. The expression level
of the SLE-risk haplotype and the total expression level of
STAT4werecorrelatedwiththeSLE-riskhaplotypeusingatwo-
tailed t-test. A logistic regression model was used to estimate
gene–gene interaction between the STAT4 and IRF5 SNPs
and for the additive effects of the three SNPs. Fisher’s exact
test was used to test for the difference in STAT4 and IRF5-risk
allele counts between Cases and Controls. These analyses
wereperformedusingR-softwareandenvironment.Clinicalcri-
teriawereanalyzed usingStatViewsoftware.Fisher’sexacttest
wasusedforcomparingthefrequenciesofACRcriteriabetween
Cases and Controls and continuous variables were compared
using Mann–Whitney U test.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG Online.
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